Principal Financial Group
CSTL icon

Principal Financial Group’s Castle Biosciences CSTL Stock Holding History

Principal Financial Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.5M Sell
1,769,877
-37,767
-2% -$1.24M 0.02% 529
2025
Q4 		$70.3M Buy
1,807,644
+13,289
+0.7% +$428K 0.04% 366
2025
Q3 		$40.9M Sell
1,794,355
-4,619
-0.3% -$93.8K 0.02% 533
2025
Q2 		$36.7M Buy
1,798,974
+331,101
+23% +$6.13M 0.02% 560
2025
Q1 		$29.4M Buy
1,467,873
+32,208
+2% +$797K 0.02% 629
2024
Q4 		$38.3M Sell
1,435,665
-102,855
-7% -$3.13M 0.02% 547
2024
Q3 		$43.9M Buy
1,538,520
+40,377
+3% +$1.03M 0.02% 508
2024
Q2 		$32.6M Sell
1,498,143
-34,329
-2% -$765K 0.02% 607
2024
Q1 		$33.9M Sell
1,532,472
-53,201
-3% -$1.16M 0.02% 623
2023
Q4 		$34.2M Buy
1,585,673
+103,503
+7% +$1.82M 0.02% 581
2023
Q3 		$25M Buy
1,482,170
+122,169
+9% +$2.14M 0.02% 690
2023
Q2 		$18.7M Buy
1,360,001
+72,854
+6% +$1.48M 0.01% 889
2023
Q1 		$29.2M Buy
1,287,147
+376,327
+41% +$9.19M 0.02% 634
2022
Q4 		$21.4M Buy
910,820
+475,080
+109% +$11M 0.02% 781
2022
Q3 		$11.4M Buy
435,740
+186,064
+75% +$5.22M 0.01% 1116
2022
Q2 		$5.48M Buy
249,676
+72,226
+41% +$1.68M ﹤0.01% 1522
2022
Q1 		$7.96M Sell
177,450
-5,217
-3% -$216K 0.01% 1496
2021
Q4 		$7.83M Buy
182,667
+12,851
+8% +$672K ﹤0.01% 1513
2021
Q3 		$11.3M Buy
169,816
+989
+0.6% +$69.6K 0.01% 1343
2021
Q2 		$12.4M Buy
168,827
+80,263
+91% +$5.3M 0.01% 1321
2021
Q1 		$6.06M Buy
88,564
+10,212
+13% +$768K ﹤0.01% 1605
2020
Q4 		$5.26M Buy
78,352
+50,052
+177% +$2.71M ﹤0.01% 1545
2020
Q3 		$1.46M Buy
28,300
+1,800
+7% +$80.1K ﹤0.01% 1801
2020
Q2 		$999K Buy
+26,500
New +$905K ﹤0.01% 1831

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Principal Financial Group's CSTL Position: Q1 2026 in Review

Principal Financial Group reduced its Castle Biosciences (CSTL) stake by 2.1% in Q1 2026, selling an estimated $1.24M and leaving 1,769,877 shares worth $43.5M. The position accounts for 0.02% of the portfolio, ranked #529.

Principal Financial Group first reported a position in CSTL in Q2 2020 and has held it in 24 quarters since. The position peaked at $70.3M in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Principal Financial Group held 1,769,877 shares of Castle Biosciences worth $43.5M as of Q1 2026.
  • Principal Financial Group sold 37,767 Castle Biosciences shares in Q1 2026, an estimated $1.24M.
  • Castle Biosciences made up 0.02% of Principal Financial Group's portfolio in Q1 2026, its #529 holding.
  • Principal Financial Group first reported a position in Castle Biosciences in Q2 2020 and has held it in 24 quarters since.
  • Principal Financial Group's Castle Biosciences position peaked at $70.3M in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Principal Financial Group's 13F filing for Q1 2026, filed 4 May 2026.